Combination therapy for the treatment of Crohn’s disease

Bibliography

• Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol 2012;26(11):811-17
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46-54
   PubMed Web of Science ®Google Scholar
• Aamodt G, Jahnsen J, Bengtson MB, et al. Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990-1993. Inflamm Bowel Dis 2008;14(7):984-91
   PubMed Web of Science ®Google Scholar
• Levesque BG, Sandborn WJ, Ruel J, et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 2015;148(1):37-51
   PubMed Web of Science ®Google Scholar
• Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of Crohn’s disease. Clin Gastroenterol Hepatol 2015;13(6):1042-50
   PubMed Web of Science ®Google Scholar
• Bouguen G, Levesque BG, Pola S, et al. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2014;12(6):978-85
   PubMed Web of Science ®Google Scholar
• Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 2013;72(6):858-62
   PubMed Web of Science ®Google Scholar
• Liao KP, Weinblatt ME, Cui J, et al. Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study. Rheumatology (Oxford) 2011;50(8):1473-9
   PubMed Web of Science ®Google Scholar
• Decker JL, Mainland D. Assessment of drug efficacy in rheumatoid arthritis. N Engl J Med 1970;283(17):928-9
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86(2):249-66
   PubMed Web of Science ®Google Scholar
• Summers RW, Switz DM, Sessions JTJr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979;77(4 Pt 2):847-69
   PubMed Web of Science ®Google Scholar
• Singleton JW, Law DH, Kelley MLJr, et al. National Cooperative Crohn’s Disease Study: adverse reactions to study drugs. Gastroenterology 1979;77(4 Pt 2):870-82
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease. Cochrane Database Syst Rev 2005(1):CD003715
   Google Scholar
• Gordon M, Naidoo K, Thomas AG, et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn’s disease. Cochrane Database Syst Rev 2011(1):CD008414
   Google Scholar
• Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev 2010(12):CD008870
   Google Scholar
• Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995;37(5):674-8
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000;119(4):895-902
   PubMed Web of Science ®Google Scholar
• Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302(18):981-7
   PubMed Web of Science ®Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000;342(22):1627-32
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995;332(5):292-7
   PubMed Web of Science ®Google Scholar
• Swaminath A, Lebwohl B, Capiak KM, et al. Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn’s disease: a US national practice survey comparing experts and non-experts. Dig Dis Sci 2011;56(4):1160-4
   PubMed Web of Science ®Google Scholar
• Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am 2014;24(3):367-78
   PubMedGoogle Scholar
• Bryant RV, Winer S, Travis SP, et al. Systematic review: histological remission in inflammatory bowel disease. Is ’complete’ remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014;8(12):1582-97
   PubMed Web of Science ®Google Scholar
• Khanna R, Bouguen G, Feagan BG, et al. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn’s disease: recommendations for clinical trial design. Inflamm Bowel Dis 2014;20(10):1850-61
   PubMed Web of Science ®Google Scholar
• Ferrante M, Colombel JF, Sandborn WJ, et al. Validation of endoscopic activity scores in patients with Crohn’s disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013;145(5):978-86
   PubMed Web of Science ®Google Scholar
• Mojtahed A, Khanna R, Sandborn WJ, et al. Assessment of histologic disease activity in Crohn’s disease: a systematic review. Inflamm Bowel Dis 2014;20(11):2092-103
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Nugent Z, Targownik LE, et al. Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut 2014. [Epub ahead of print]
   Google Scholar
• Floyd DN, Langham S, Severac HC, et al. The economic and quality-of-life burden of Crohn’s disease in Europe and the United States, 2000 to 2013: a systematic review. Dig Dis Sci 2015;60(2):299-312
   PubMed Web of Science ®Google Scholar
• Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005;54(2):237-41
   PubMed Web of Science ®Google Scholar
• Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 2013;145(4):766-74
   PubMed Web of Science ®Google Scholar
• Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology 2013;145(4):758-65
   PubMed Web of Science ®Google Scholar
• Donovan M, Lunney K, Carter-Pokras O, et al. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci 2007;52(8):1798-805
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007;56(9):1226-31
   PubMed Web of Science ®Google Scholar
• Bose F, Raeli L, Garutti C, et al. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues. Clin Immunol 2011;139(2):164-76
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003;348(7):601-8
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9
   PubMed Web of Science ®Google Scholar
• Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130(4):1054-61
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371(9613):660-7
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362(15):1383-95
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52(11):3381-90
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54(1):26-37
   PubMed Web of Science ®Google Scholar
• Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383(9914):321-32
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology 2014;146(3):681-8
   PubMed Web of Science ®Google Scholar
• Khanna R, Levesque BG, Bressler B, et al. Early combined immunosuppression for the management of Crohn’s disease: A community-based cluster randomized trial. Gastroenterology 2014;146:S-187
   Google Scholar
• Khanna R, Bressler B, Levesque BG, et al. A cluster randomization trial of early combined immunosuppression for the management of Crohn’s disease. The Lancet 2015; In press
   PubMedGoogle Scholar
• Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol 2011;106(4):674-84
   PubMed Web of Science ®Google Scholar
• Assa A, Hartman C, Weiss B, et al. Long-term outcome of tumor necrosis factor alpha antagonist’s treatment in pediatric Crohn’s disease. J Crohns Colitis 2013;7(5):369-76
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 2009;58(4):492-500
   PubMed Web of Science ®Google Scholar
• Chaparro M, Guerra I, Munoz-Linares P, et al. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:971-86
   PubMed Web of Science ®Google Scholar
• Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn’s disease. Aliment Pharmacol Ther 2014;39(10):1126-35
   PubMed Web of Science ®Google Scholar
• Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patients. J Crohns Colitis 2013;7(2):154-60
   PubMed Web of Science ®Google Scholar
• Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology 2009;137(5):1628-40
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Larsson L, Truedsson L, et al. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 2006;8(4):R131
   PubMed Web of Science ®Google Scholar
• Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005;11(5):442-6
   PubMed Web of Science ®Google Scholar
• Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98(6):1315-24
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EVJr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105(5):1133-9
   PubMed Web of Science ®Google Scholar
• Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn’s disease. Eur J Gastroenterol Hepatol 2011;23(12):1100-10
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EVJr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134(4):929-36
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107(9):1409-22
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107(7):1051-63
   PubMed Web of Science ®Google Scholar
• Scott FI, Vajravelu RK, Bewtra M, et al. The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a Markov model. Clin Gastroenterol Hepatol 2015;13(2):302-9
   PubMed Web of Science ®Google Scholar
• Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370(9581):59-67
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: A meta-analysis. Clin Gastroenterol Hepatol 2015;13(5):847-58
   PubMed Web of Science ®Google Scholar
• Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014;39(5):447-58
   PubMed Web of Science ®Google Scholar
• Abbas AM, Almukhtar RM, Loftus EVJr, et al. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol 2014;109(11):1781-93
   PubMed Web of Science ®Google Scholar
• Siegel CA, Finlayson SR, Sands BE, et al. Adverse events do not outweigh benefits of combination therapy for Crohn’s disease in a decision analytic model. Clin Gastroenterol Hepatol 2012;10(1):46-51
   PubMed Web of Science ®Google Scholar
• Jones J, Kaplan GG, Peyrin-Biroulet L, et al. Impact of concomitant immunomodulator treatment on efficacy and safety of Anti-TNF Therapy in Crohn’s disease: A meta-analysis of placebo controlled trials with individual patient-level Data. Gastroenterology 2013;144(5):S-179
   Google Scholar
• Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014;311(23):2406-13
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9(1):36-41
   PubMed Web of Science ®Google Scholar
• Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013;108(1):99-105
   PubMed Web of Science ®Google Scholar
• Beaugerie L. Use of immunosuppressants and biologicals in patients with previous cancer. Dig Dis 2013;31(2):254-9
   PubMed Web of Science ®Google Scholar
• Bernheim O, Colombel JF, Ullman TA, et al. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013;62(11):1523-8
   PubMed Web of Science ®Google Scholar
• Duarte R, Campainha S, Cotter J, et al. Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy. Acta Reumatol Port 2012;37(3):253-9
   PubMed Web of Science ®Google Scholar
• Kane S. Preparing the patient for immunosuppressive therapy. Curr Gastroenterol Rep 2010;12(6):502-6
   PubMedGoogle Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369(8):711-21
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Xu J, et al. Efficacy of induction treatment with vedolizumab for patients with Crohn’s disease who have experienced tumour necrosis factor antagonist failure or are tumour necrosis factor antagonist naive. J Crohn’s Colitis 2014;8:S50
   Google Scholar
• FDA. New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab). 2012. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm288186.htm
   Google Scholar
• Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, et al. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 2012;71(7):604-17
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005;353(4):362-8
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340(18):1398-405
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337(15):1029-35
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350(9):876-85
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130(2):323-33
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007;56(9):1232-9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357(3):228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007;357(3):239-50
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005;129(3):807-18
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JWD, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology 2014;146(3):681-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005;353(18):1912-25
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology 2007;132(5):1672-83
   PubMed Web of Science ®Google Scholar
• Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007;13(1):2-11
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn W, Rutgeerts PJ, et al. Efficacy of vedolizumab induction therapy in patients with Crohn’s disease who have experienced tumor necrosis factor antagonist failure or are tumor necrosis factor antagonist naive. Gastroenterology 2014;1:S-149
   Google Scholar